Discover NEW published data on the advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials. Learn how Signatera, awarded 3 breakthrough technology designations, can be applied in early stage and late stage cancer trials, enriching for patients potentially most likely to respond to therapy, accelerating time to trial readout, and identifying early relapsers.

Topics will include:

• Latest clinical data in bladder, ovarian and breast cancers from 2021 publications and presentations
• Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection
• Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout